Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
214 Wu <strong>and</strong> von Eckardste<strong>in</strong><br />
107. Franks S, Gill<strong>in</strong>g-Smith C, Watson H, Willis D. Insul<strong>in</strong> action <strong>in</strong> the normal <strong>and</strong> polycystic ovary.<br />
Endocr<strong>in</strong>ol Metab Cl<strong>in</strong> North Am 1999;28(2):361–378.<br />
108. Acién P, Quereda F, Matall<strong>in</strong> P, et al. Insul<strong>in</strong>, <strong>and</strong>rogens, <strong>and</strong> obesity <strong>in</strong> women with <strong>and</strong><br />
withoutpolycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999;72:<br />
32–40.<br />
109. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insul<strong>in</strong> stimulates testosterone biosynthesis by<br />
human thecal cells from women with polycystic ovary syndrome by activat<strong>in</strong>g its own receptor <strong>and</strong><br />
us<strong>in</strong>g <strong>in</strong>ositolglycan mediators as the signal transduction system. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab<br />
1998;83:2001–2005.<br />
110. Dunaif A, Thomas A. Current concepts <strong>in</strong> the polycystic ovarian syndrome. Ann Rev Med<br />
2001;52:401–419.<br />
111. Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metform<strong>in</strong> on <strong>in</strong>sul<strong>in</strong> secretion, <strong>in</strong>sul<strong>in</strong><br />
action, <strong>and</strong> ovarian steroidogenesis <strong>in</strong> women with polycystic ovary syndrome. J Cl<strong>in</strong> Endocr<strong>in</strong>ol<br />
Metab 1997;82:524–530.<br />
112. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metform<strong>in</strong> therapy is associated with a decrease<br />
<strong>in</strong> plasma plasm<strong>in</strong>ogen activator <strong>in</strong>hibitor 1, lipoprote<strong>in</strong>(a), <strong>and</strong> immunoreactive <strong>in</strong>sul<strong>in</strong> levels <strong>in</strong><br />
patients with the polycystic ovary syndrome. Metabolism 1997;46:454–457.<br />
113. Pasquali R, Filicori M. Insul<strong>in</strong> sensitiz<strong>in</strong>g agents <strong>and</strong> polycystic ovary syndrome. Eur J Endocr<strong>in</strong>ol<br />
1998;138:253–254.<br />
114. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metform<strong>in</strong> therapy decreases<br />
hyper<strong>and</strong>rogenism <strong>and</strong> hyper<strong>in</strong>sul<strong>in</strong>emia <strong>in</strong> women with polycystic ovary syndrome. Fertil Steril<br />
2000;73:1149–1154.<br />
115. Dahlgren E, L<strong>and</strong><strong>in</strong> K, Krotkiewski M, et al. Effects of two anti<strong>and</strong>rogen treatments on hirsutism <strong>and</strong><br />
<strong>in</strong>sul<strong>in</strong> sensitivity <strong>in</strong> women with polycystic ovary syndrome. Hum Reprod 1998;13:2706–2711.<br />
116. Morghetti P, Tosi F, Castello R et al. The <strong>in</strong>sul<strong>in</strong> resistance <strong>in</strong> women with hyper<strong>and</strong>rogenism is<br />
partially reversed by anti<strong>and</strong>rogen treatment: evidence that <strong>and</strong>rogens impair <strong>in</strong>sul<strong>in</strong> action <strong>in</strong><br />
women. J Cl<strong>in</strong> endocr<strong>in</strong>ol Metab 1997;81:952–960.<br />
117. Diamanti-K<strong>and</strong>arakis E, Mitrakou A, Raptis S, et al. The effect of a pure anti<strong>and</strong>rogen receptor<br />
blocker, flutamide, on the lipid profile <strong>in</strong> the polycystic ovary syndrome. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab<br />
1998;83:2699–2705.<br />
118. Lemieux S, Lewis GF, Ben-Chetrit A, et al. Correction of hyper<strong>and</strong>rogenemia by laparoscopic<br />
ovarian cautery <strong>in</strong> women with polycystic ovarian syndrome is not accompanied by improved<br />
<strong>in</strong>sul<strong>in</strong> sensitivity or lipid-lipoprote<strong>in</strong> levels. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1999;84:4278–4282.<br />
119. Polderman KH, Gooren LJ, Asschermann H et al. Induction of <strong>in</strong>sul<strong>in</strong> resistance by <strong>and</strong>rogens <strong>and</strong><br />
estrogens. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1994;79:265––271.<br />
120. Elbers JM, de Jong S, Teerl<strong>in</strong>k T, et al. Changes <strong>in</strong> fat cell size <strong>and</strong> <strong>in</strong> vitro lipolytic activity of<br />
abdom<strong>in</strong>al <strong>and</strong> gluteal adipocytes after a one-year cross-sex hormone adm<strong>in</strong>istration <strong>in</strong> transsexuals.<br />
Metabolism 1999;48(11):1371–1377.<br />
121. Lovejoy JC, Bray GA, Bourgeois MO, et al. Exogenous <strong>and</strong>rogens <strong>in</strong>fluence body composition <strong>and</strong><br />
regional body fat distribution <strong>in</strong> obese postmenopausal women - a cl<strong>in</strong>ical research center study. J<br />
Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1996;81(6):2198–2203.<br />
122. Nilsson C, Niklasson M, Eriksson E, et al. Impr<strong>in</strong>t<strong>in</strong>g of female offspr<strong>in</strong>g with testosterone results<br />
<strong>in</strong> <strong>in</strong>sul<strong>in</strong> resistance <strong>and</strong> changes <strong>in</strong> body fat distribution at adult age <strong>in</strong> rats. J Cl<strong>in</strong> Invest<br />
1998;101(1):74–78.<br />
123. Dunaif A. Insul<strong>in</strong> resistance <strong>and</strong> the polycystic ovary syndrome: mechanism <strong>and</strong> implications for<br />
pathogenesis. Endocr Rev 1997;18:774–800.<br />
124. Rosenfield RL. Ovarian <strong>and</strong> adrenal function <strong>in</strong> polycystic ovary syndrome. Endocr<strong>in</strong>ol Metab Cl<strong>in</strong><br />
North Am 1999;28:265–293.<br />
125. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory <strong>and</strong> metabolic effects of d-chiro-<strong>in</strong>ositol <strong>in</strong><br />
the polycystic ovary syndrome. N Eng J Med 1999;340:1314–1320.<br />
126. Valdemarsson S, Hedner P, Nilsson-Ehle P. Increase <strong>in</strong> hepatic lipase activity after testosterone<br />
substitution <strong>in</strong> men with hypogonadism of pituitary orig<strong>in</strong>. Acta Med Sc<strong>and</strong> 1987;221:363–366.<br />
127. Kirkl<strong>and</strong> RT, Keenan BS, Probstfield JL, et al. Decrease <strong>in</strong> plasma high density lipoprote<strong>in</strong> cholesterol<br />
levels at puberty <strong>in</strong> boys with delayed adolescence: Correlation with plasma testosterone levels<br />
JAMA 1987;257:502–507.<br />
128. Sorva R, Kuusi T, Task<strong>in</strong>ene MR, et al. Testosterone substitution <strong>in</strong>creases the activity of lipoprote<strong>in</strong><br />
lipase <strong>and</strong> hepatic lipase <strong>in</strong> hypogonadal men. Atherosclerosis 1988;69:191–197.